Background
OI and XLH are the two most common metabolic bone conditions seen in the Bone Health Clinic at the Royal Children’s Hospital (RCH). The transition period for these patients represents a current challenge due to the lack of guidelines and standardised processes.
Aim
To evaluate the 1) QoL outcomes using a disease-specific questionnaire for patients with OI (1) and 2) Strengths and challenges of the current transition model.
Method
A cross sectional survey using questionnaires was given to OI and XLH patients of the RCH and staff involved in transition care.
Results
118 questionnaires were sent; 5 were returned to sender (incorrect address). 42 questionnaires were completed (33 patients with OI, 7 patients with XLH and 2 staff members). Patient characteristics are reported in Table 1.
In the OI cohort, increasing age correlated with lower “being careful” scores (r=-0.23, R2=0.0698) and higher “pain” scores (r=0.35, R2=0.0688). There was no correlation between QoL and the number of bisphosphonate doses received.
Themes surrounding the transition period for patients with OI and XLH included “unfamiliar”, “frustrating”, “no continuity of care” and “lack of understanding”. Suggestions for improvements included “5-year plan”, “valid referral”, “education”, “clear transition plans” and “consistency”.
Following transition from the RCH, patients received care (patient-reported) from a private endocrinologist (9/17, 53%) or public hospital (2/17, 12%). 6 patients (35%) received no ongoing care. Referrals to adult care (patient-reported) were organised by the RCH (6/17, 35%), GP (4/17, 24%) and emergency department (2/17, 12%).
Conclusion
The transition period is a challenging and frustrating time for our patients, with over one third no longer receiving care. A prospective trial is required to evaluate outcomes following the implementation of consistent guidelines and/or a personalised transfer tool.